AUM Pharmacy
Health Hub
Search Icon

AUM Pharmacy

Hi there!

Hello, Login
All Categories
VisaVisaVisa
slide-0
slide-1

Ripaglip M 50/500 Tablet ER

Prescription Icon
Prescription Required

Marketer

Ripca Pharmaceutical Pvt Ltd

Salt Composition

Metformin (500mg) + Vildagliptin (50mg)

Overview Ripaglip M 50/500 Tablet ER

Metformin/glimepiride extended-release tablets (50/500 mg) manage elevated blood glucose in individuals with type 2 diabetes. This dual-action medication mitigates the risk of severe diabetic complications, such as renal impairment and vision loss, and may lessen the likelihood of cardiovascular events. This medication may be used independently or in conjunction with other antidiabetic therapies. Optimal efficacy necessitates adherence to a balanced diet and regular physical activity. Dosage is personalized, considering individual health status, glucose levels, and concurrent medications. Consuming the medication with food minimizes gastrointestinal distress. Consistent daily dosing is crucial for maximizing therapeutic benefits; discontinuation should only occur under medical supervision. Effective blood sugar control helps prevent future complications. Continued commitment to the prescribed diet and exercise regime is essential. Lifestyle choices significantly impact diabetes management. Common adverse effects include diarrhea, nausea, vomiting, indigestion, cephalalgia, pharyngitis, asthenia, GERD, hyperhidrosis, and anorexia. Hypoglycemia is a potential side effect when used with insulin or sulfonylureas; appropriate recognition and management strategies are vital. This treatment isn't universally suitable. Pre-existing kidney, liver, or heart conditions, pancreatic issues, or significant alcohol consumption should be disclosed to your physician before commencing treatment. Pregnant or lactating individuals require medical consultation prior to use. Potential drug interactions necessitate comprehensive disclosure of all medications to ensure patient safety. Alcohol consumption should be minimized due to its hypoglycemic effect. Renal function and blood glucose levels will be monitored by your doctor throughout treatment.

Uses of Ripaglip M 50/500 Tablet ER

Managing Type 2 Diabetes

Major Benefits of Ripaglip M 50/500 Tablet ER:

Follow your doctor's instructions precisely regarding dosage and treatment length for this medication. Ingest the Ripaglip M 50/500 Tablet ER whole; avoid crushing, chewing, or breaking it. Administer this medication with a meal.

Common Side effects of Ripaglip M 50/500 Tablet ER:

  • Hypoglycemia (low blood glucose level)
  • Trembling
  • Headache
  • Dizziness
  • Nausea
  • Weakness
  • Gastro-esophageal reflux disease
  • Increased sweating
  • Decreased appetite

How to use Ripaglip M 50/500 Tablet ER:

Consume this medication precisely as directed by your physician, adhering to the prescribed dosage and treatment period. Ingest the tablet whole; avoid chewing, crushing, or fracturing it. Administer Ripaglip M 50/500 Extended-Release Tablet with a meal.

How Ripaglip M 50/500 Tablet ER works:

Metformin and glimepiride extended-release tablets, sold as Ripaglip M 50/500, offer dual anti-diabetic action.

SAFETY ADVICE

AlcoholAlcoholUNSAFE

Combining alcohol and Ripaglip M 50/500 Tablet ER is unsafe.

PregnancyPregnancyCONSULT YOUR DOCTOR

Use of Ripaglip M 50/500 Extended-Release tablets during pregnancy may pose risks. While human data is scarce, animal research indicates potential harm to the fetus. A physician will assess the potential advantages against any possible risks prior to prescription. Seek medical advice.

Breast feedingBreast feedingCONSULT YOUR DOCTOR

Extended-release Ripaglipine 50/500 mg tablets are likely unsafe for breastfeeding mothers. Available human data indicates potential transfer to breast milk, posing a risk to the infant.

DrivingDrivingCAUTION

Driving may be impaired by abnormally low or high blood sugar levels. Refrain from driving if such symptoms arise.

KidneyKidneyCAUTION

Exercise caution when administering Ripaglip M 50/500 Extended-Release tablets to individuals with impaired renal function. Dosage modification of Ripaglip M 50/500 Extended-Release tablets may be necessary. Physician consultation is advised.

LiverLiverUNSAFE

Extended-release Ripaglipin 50/500mg tablets are contraindicated in individuals with hepatic impairment and should be avoided. Medical advice is recommended.

What if you forget to take Ripaglip M 50/500 Tablet ER :

Should you forget to take a Ripaglip M 50/500 Tablet ER, administer it immediately. Nevertheless, if your next scheduled dose is imminent, omit the missed dose and resume your usual regimen. Avoid taking a double dose.

Facts to Know About Ripaglip M 50/500 Tablet ER

LabelValue
Developing Habits No.
Treatment Category Diabetes Management

FAQs on Ripaglip M 50/500 Tablet ER

Ripaglip M 50/500 ER tablets rarely cause hypoglycemia by themselves. However, low blood sugar can result from inadequate calorie intake while using this medication. Symptoms include nausea, headache, irritability, hunger, sweating, dizziness, rapid heartbeat, and anxiety or shakiness. These symptoms are more pronounced if meals are missed or delayed, alcohol is consumed, excessive exercise is undertaken, or other antidiabetic medications are used concurrently. Regular blood sugar monitoring is crucial. Always carry a fast-acting sugar source, such as glucose tablets, honey, or fruit juice.
Nausea and vomiting are possible side effects of Ripaglip M 50/500 Tablet ER. If vomiting occurs, sip small amounts of water or other fluids frequently. Consult your doctor if vomiting continues or you experience dehydration symptoms such as dark, strong-smelling urine and infrequent urination. Do not take other medications without first consulting your doctor.
Patients with allergies to Ripaglip M 50/500 Tablet ER components or excipients, or those with severe kidney or liver impairment, congestive heart failure, lactic acidosis, or diabetic ketoacidosis, should not use this medication.
Store this medication in its original, tightly closed container, following the label's instructions. Discard any unused medication and keep it out of reach of children, pets, and others.
Ripaglip M 50/500 ER tablets combine metformin (a biguanide) and vildagliptin, both anti-diabetic medications. Metformin reduces liver glucose production, slows intestinal glucose absorption, and enhances insulin sensitivity. Vildagliptin, a DPP-4 inhibitor, boosts pancreatic insulin release. This combination is contraindicated for individuals under 18.
Ripaglip M 50/500 Tablet ER can cause lactic acidosis, a serious medical emergency characterized by excessive blood lactic acid (also known as MALA, or Metformin-associated lactic acidosis). This rare side effect necessitates avoidance in patients with kidney disease, the elderly, or those who consume significant alcohol. Symptoms include muscle pain/weakness, dizziness, fatigue, cold extremities, shortness of breath, nausea, vomiting, abdominal pain, and bradycardia. If you experience these, discontinue Ripaglip M 50/500 Tablet ER and seek immediate medical attention.
Prolonged use of Ripaglip M 50/500 Tablet ER can lead to vitamin B12 deficiency by hindering its absorption in the stomach. This deficiency, if left unaddressed, may result in anemia and neurological complications.
Ripaglip M 50/500 Tablet ER is safe when used as directed by your doctor. However, even with proper use, you may experience side effects such as nausea, diarrhea, vomiting, upset stomach, headache, nasal congestion, sore throat, respiratory infection, or low blood sugar (hypoglycemia, especially if combined with insulin or sulfonylurea). Report any persistent issues to your physician.
Ripaglip M 50/500 Tablet ...
80
MRP 98
18% off